Skip to content

Author

Qiong-Liu Yu

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Paving the way for immunotherapy: Simvastatin-primed dual-targeting NPTAC overcomes immune resistance in hepatocellular carcinoma.

A "Pave the Way Strategy" combining simvastatin (SIM) with a dual-targeted nanoparticle-mediated targeting chimera (Hs/αPD-L1-NPTAC) enables precise HCC targeting and synchronous intracellular functions and provides a promising approach to overcome ICB resistance and enable precision immunotherapy for HCC.

Chen Chen, Quanwei Sun, Qiong-Liu Yu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.